Report: Teva To Pay $512M In Class Action Suit

April 21, 2015 | According to a “Reuters” report, Teva Pharmaceutical Industries has agreed to pay $512 million in a class action suit. The suit claims that a Teva-acquired company Cephalon “used anticompetitive settlements to delay generic versions of its wakefulness drug Provigil.” Also according to “Reuters,” “the settlement is the largest ever to be paid to consumers over allegations of delaying generic drugs, according to a motion to approve the settlement filed Friday in Philadelphia.” Teva was founded in 1901 and is headed by Erez Vigodman.